Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

05 January 2022 | Wednesday | News

Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
Image Source : Public Domain

Image Source : Public Domain

"We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo. "Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic products—and our reputation for dependable quality is an especially essential factor when treating children."

According to IQVIA, CUVPOSA® sales were approximately $27 million for the 12 months ended October 31, 2021.

CUVPOSA® is a registered trademark of Merz Pharmaceuticals, LLC.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in